Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -0.04% is 100% above its 5-year average of -323.01%, near the high end of its 5-year range (-12153.04%–79.19%).
99.99% above its 12-month average of -674.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -2921.71%.
EBITDA MARGIN
-0.04%
EBITDA MARGIN AVG TTM
-674.74%
EBITDA MARGIN AVG 3Y
-195.42%
EBITDA MARGIN AVG 5Y
-323.01%
EBITDA MARGIN AVG 10Y
-905.36%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.99%
CURRENT VS 3Y AVG
+99.98%
CURRENT VS 5Y AVG
+99.99%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Spero Therapeutics, Inc.
Market Cap
$68.90M
EBITDA Margin
-0.04%
TTM Avg
-674.74%
3Y Avg
-195.42%
5Y Avg
-323.01%
Market Cap
$69.04M
EBITDA Margin
-8394.83%
TTM Avg
-8394.83%
3Y Avg
-4949.66%
5Y Avg
-3042.42%
Market Cap
$68.60M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$70.02M
EBITDA Margin
0.40%
TTM Avg
5.90%
3Y Avg
-0.59%
5Y Avg
0.99%
Market Cap
$66.56M
EBITDA Margin
-34495.00%
TTM Avg
-19432.00%
3Y Avg
-15233.78%
5Y Avg
-9657.34%
Market Cap
$71.64M
EBITDA Margin
-31.36%
TTM Avg
-442.92%
3Y Avg
-595.18%
5Y Avg
-526.87%
Market Cap
$71.74M
EBITDA Margin
-40176.79%
TTM Avg
-26409.54%
3Y Avg
-18300.96%
5Y Avg
-13878.09%
Market Cap
$66.01M
EBITDA Margin
-794.91%
TTM Avg
-458.44%
3Y Avg
-317.77%
5Y Avg
-317.77%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.90M | -0.04% | -674.74% | -195.42% | -323.01% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $69.04M | -8394.83% | -8394.83% | -4949.66% | -3042.42% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | -103.63% | -143.63% | -176.25% | -194.05% |
| Champions Oncology, Inc. (CSBR)vs › | $70.02M | 0.40% | 5.90% | -0.59% | 0.99% |
| iBio, Inc. (IBIO)vs › | $66.56M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
| Cingulate Inc. (CING)vs › | $66.54M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $71.64M | -31.36% | -442.92% | -595.18% | -526.87% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.74M | -40176.79% | -26409.54% | -18300.96% | -13878.09% |
| XBiotech Inc. (XBIT)vs › | $66.01M | -794.91% | -458.44% | -317.77% | -317.77% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.13M | -85.70% | -57.28% | -59.72% | -51.35% |
Gross Margin
100.0%
EBITDA Margin
-0.0%
Operating Margin
-0.0%
Net Margin
17.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -2921.71% |
| 2025-12-31 | 79.19% |
| 2025-09-30 | -259.69% |
| 2025-06-30 | -20.70% |
| 2025-03-31 | -250.77% |
| 2024-12-31 | -144.41% |
| 2024-09-30 | -138.03% |
| 2024-06-30 | -186.92% |
| 2024-03-31 | -332.59% |
| 2023-12-31 | 68.78% |
| 2023-09-30 | -7.17% |
| 2023-06-30 | -470.62% |
| 2023-03-31 | -682.17% |
| 2022-12-31 | 56.20% |
| 2022-09-30 | -1069.96% |
| 2022-06-30 | -2877.90% |
| 2022-03-31 | -12153.04% |
| 2021-12-31 | -995.30% |
| 2021-09-30 | -3160.45% |
| 2021-06-30 | -873.41% |
| 2021-03-31 | -263.62% |
| 2020-12-31 | -975.62% |
| 2020-09-30 | -471.31% |
| 2020-06-30 | -1058.83% |
| 2020-03-31 | -1330.51% |
| 2019-12-31 | -707.87% |
| 2019-09-30 | -10172.09% |
| 2019-06-30 | -624.49% |
| 2019-03-31 | -144.79% |
| 2018-12-31 | -646.87% |
| 2018-09-30 | -1649.54% |
| 2018-06-30 | -2133.26% |
| 2018-03-31 | -929.84% |
| 2017-12-31 | -1399.90% |
| 2017-09-30 | -1653.60% |
| 2017-06-30 | -4049.00% |
| 2017-03-31 | -5365.71% |
| 2016-12-31 | -2604.48% |
